Year 2021 / Volume 113 / Number 5
Original
Tailored Helicobacter pylori eradication therapy in obese patients undergoing bariatric surgery

345-347

DOI: 10.17235/reed.2020.7433/2020

Oscar Laudanno, Gabriel Ahumarán, Pablo Gollo, Marina Khoury, Marcelo Thomé, Patricia González,

Abstract
Objectives: to compare the efficacy and safety of a tailored quadruple concomitant therapy based on body weight, with the same scheme but with fixed doses in obese patients undergoing bariatric surgery. Methods: a prospective study was performed of 104 obese patients. Results: the weight-based therapy group achieved significantly higher eradication rates in the intention-to-treat analysis; 86.3 % (95 % CI: 74.3-93.2) vs 66.1 % (95 % CI: 52.6-77.3), p < 0.05. Relative risk: 1.31 (95 % CI: 1.05-1.63). Discontinuations and adverse events were similar in both groups. Conclusions: a tailored quadruple concomitant therapy based on body weight seems to be more effective than the standard quadruple concomitant therapy in obese patients.
Share Button
New comment
Comments
No comments for this article
References
1. Fried M, Hainer V, Basdevant A, et al. Interdisciplinary European Guidelines on Surgery of Severe Obesity. Obesity Facts 2008;1:52-59
2. Evans J, Muthusamy V, Acosta D, et al. American Society for Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in the bariatric surgery patient. Gastrointestinal Endoscopy 2015;81:1063-1072
3. Abdullahi M, Annibale B, Capoccia D, et al. Eradication of Helicobacter pylori is affected by body mass index (BMI). Obesity Surgery 2008;18:1450-1454.
4. Laudanno O, Ahumarán G, Thomé M, et al. Erradicación Helicobacter pylori en pacientes obesos pre-cirugía bariátrica. Acta Gastroenterológica Latinoamericana 2020;50(1):40-44
5. Cuesta Hernández M, Pérez Peña C, Matía Martín P, et al. Helicobacter Pylori (HP) infection in obese patients undergoing Roux-en-Y gastric bypass efficacy of two different treatment regimens in HP eradication. Nutrición Hospitalaria 2015;32:600-605
6. Carabotti M, D´Ercole C, Iossa A, et al. Helicobacter Pylori infection in obesity and its clinical outcome after bariatric surgery. World J Gastroenterology 2014;20:647-653
7. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in obese? Br J Clin Pharmacol 2004;58:119-33
8. Jain R, Chung SM, Lian J, et al. Implications of Obesity for Drug Therapy: Limitations and Challenges. Clinical Pharmacology & Therapeutics 2011,90:77-89
9. Meng L, Mui E, Holubar M, et al. Comprehensive Guidance for Antibiotic Dosing in Obese Adults. Pharmacotherapy 2017;11:1415-31
10. Falagos M, Karageorgogoulos D. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010;375:248-51
11. Malfertheiner P, Megraud F, O´Morain C, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664
12. Knibbe C, Brill M, van Rongen A. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol 2015;149:149-67
13. Smit C, De Hoogd S, Brüggemann R, et al. Obesity and drug pharmacology: review of the influence of obesity on pharmacokinetic and pharmacodynamics parameters. Expert Opinion on Drug Metabolism & Toxicology 2018,14:275-85
14. Pintar T, Kaliterna N, Carli T. The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery. Journal of International Medical Research 2018;46:2696-2707
15. Fernandez Salazar L, Valle Muñoz J. Treating Helicobacter pylori infection in the face of growing antibiotic resistance. Rev Esp Enferm Dig 2019; 111:653-654
Related articles

Special Article

V Spanish Consensus Conference on Helicobacter pylori infection treatment

DOI: 10.17235/reed.2021.8358/2021

Letter to the Editor

A question about dyspeptic patients analyzed using psychometric scores

DOI: 10.17235/reed.2017.5401/2017

Letter to the Editor

GETTEMO position statement on bariatric endoscopic techniques as a voluntary medicine

DOI: 10.17235/reed.2017.5144/2017

Original

Usefulness of an intra-gastric balloon before bariatric surgery

DOI: 10.17235/reed.2017.4624/2016

Original

Multicenter study on the safety of bariatric endoscopy

DOI: 10.17235/reed.2017.4499/2016

Letter to the Editor

Acute psychotic episode secondary to Helicobacter pylori eradication treatment

DOI: 10.17235/reed.2017.4482/2016

Citation tools
Laudanno O, Ahumarán G, Gollo P, Khoury M, Thomé M, González P, et all. Tailored Helicobacter pylori eradication therapy in obese patients undergoing bariatric surgery. 7433/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 2588 visits.
This article has been downloaded 312 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 25/07/2020

Accepted: 07/08/2020

Online First: 27/11/2020

Published: 10/05/2021

Article revision time: 9 days

Article Online First time: 125 days

Article editing time: 289 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology